| Literature DB >> 28573252 |
Lamiae Belayachi1,2, Clara Aceves-Luquero2, Nawel Merghoub3, Silvia Fernández de Mattos2,4, Saaîd Amzazi1, Priam Villalonga2,4, Youssef Bakri1.
Abstract
BACKGROUND: Ormenis eriolepis Coss (Asteraceae) is an endemic Moroccan subspecies, traditionally named "Hellala" or "Fergoga". It's usually used for its hypoglycemic effect as well as for the treatment of stomacal pain. As far as we know, there is no scientific exploration of anti tumoral activity of Ormenis eriolepis extracts.Entities:
Keywords: Ormenis eriolepis Coss; apoptosis; bioactive compounds; cancer cell lines; cytotoxicity
Mesh:
Substances:
Year: 2017 PMID: 28573252 PMCID: PMC5446462 DOI: 10.21010/ajtcam.v14i2.37
Source DB: PubMed Journal: Afr J Tradit Complement Altern Med ISSN: 2505-0044
Figure 1Cytotoxic activity of Ormenis eriolepis organic extracts and fractions in a panel of cancer and nontransformed cell lines. A. suspension cells panel Jurkat, Jeko-1, and TK-6 and B. adherent cells panel LN229, SW620, U2OS, PC-3 and NIH3T3; were incubated for 48 h with 50 μg/ml of each extract and fraction. Results represent the mean ±SD of at least 3 independent experiments indicating the percentage of viable cells relative to vehicle-treated (control) cells. Statistically significant differences are indicated by ***p < 0.005 compared with untreated.
Figure 2(A) Dose-response analysis of Ormenis eriolepis dichloromethane fraction (Oe-DF) and IC50 determination on Jurkat and Jeko-1 cells. (B) Dose-response analysis of Ormenis eiriolepis hexanic extract (Oe-HE) and IC50 determination on LN229 and PC-3 cells. Cells were treated for 48h at different concentrations ranging from 1 to 50μg/ml; IC50 value (μg/ml) was determined graphically from the viability curves, NIH3T3 and TK6 cells were used as control. Data are expressed as means ±SD of triplicate determinations.
Figure 3cell cycle distribution analysis of Jurkat, Jeko-1, LN229 and PC-3 cells treated respectively with Ormenis eriolepis Dichloromethane Fraction (Oe-DF) and Hexanic Extract (Oe-HE) by flow cytometry. Jurkat, Jeko-1, LN229 and PC-3 cells were incubated respectively with 20 μg/ml and 50 μg/ml of Oe-DF and Oe-HE for 24h and 48h. Cells were harvested and their DNA content analysed by flow cytometry as described in Materials and Methods. The cell cycle distribution is shown for each experimental condition.
Figure 4Effect of Oe-DF and Oe-HE on p-H2AX expression levels in Jurkat, Jeko-1, LN229 and PC-3 cells. Cells (4 × 10cells /ml) were treated respectively with 20 μg/ml and 50 μg/ml of Oe-DF and Oe-HE for 0, 6 and 12h. p-H2A.X levels in cellular extracts were detected by immunoblot with specific antibodies. Tubulin was used as an internal control.
Figure 5Effect of (Oe-DF) in Jurkat and Jeko-1 cell and (Oe-HE) in LN229 and PC-3 on apoptosis induction analyzed by flow cytometry. Jurkat, Jeko-1, LN229 and PC-3 cells were incubated respectively with 20 μg/ml and 50 μg/ml of Oe-DF and Oe-HE for 12h and 24h. The x-axis shows Annexin V-FITC staining and y-axis indicates Propidium iodide staining; Lower left (LL) quadrant: viable cells; lower right (LR) quadrant: early apoptotic cells; upper left (UL) quadrant: necrotic cells, upper right (UR) quadrant: late apoptotic cells.
Figure 6Effect of Ormenis eriolepis Fraction and Extract on caspase activity induction on Jurkat, Jeko-1, LN229 and PC-3 cells. (A) Jurkat and Jeko-1 cells were treated with 20 μg/ml of (Oe-DF) for 48h and caspase activity was measured (B) LN229 and PC-3 cells were treated with 50 μg/ml of (Oe-HE) for 48h and caspase activity was measured. Results indicate the average fold increase ± S.E.M in caspase activity relative to untreated cells from three independent determinations performed in duplicate.
Figure 7Effect of Ormenis eriolepis Fraction and Extract on the viability of Jurkat, Jeko-1, LN229 and PC-3 cells in presence of a panel of signaling pathways inhibitors. (A) Jurkat and Jeko-1 (B) LN229 and PC-3 cells were untreated or treated respectively with 20 and 50 μg/ml of Oe-DF and Oe-HE in the presence or absence of SP600125, U0126; H1152, Pifithrin or Jak3 inhibitor (all at 10 μM) for 48h. Inhibitors were pre-incubated for 1 hour before the addition of Mv-DF extract. Cell viability is represented as a percentage relative to untreated cells. Data is means ± S.E.M from three independent determinations performed in duplicate.
Figure 8(A) Chromatogram of Compounds were identified by computer searches in the reference libraries of NIST and Wiley7, and fragmentation patterns were compared with literature Data. Oe-DF constituents are shown in Table 1. (B) Chromatogram of Oe-HE constituents are shown in Table 2.
Compounds present in dichloromethane fraction of Ormenis eiriolepis identified by CG/MS.
| RT | identified compounds | cas numbers | % Area |
|---|---|---|---|
| Propanoic acid,2-[(trimethylsilyl)oxy]-, trimethylsilyl ester | 17596-96-2 | 0,19604 | |
| Glycolic acid, TMS | 33581-77-0 | 0,176436 | |
| 2-(Trimethylsiloxy)propenoic acid trimethylsilyl ester | 55191-13-4 | 0,19604 | |
| Silanol, 1,1,1 -trimethyl-, 1 -benzoate | 08/12/2078 | 0,470496 | |
| Octanoic acid, trimethylsilyl ester | 55494-06-9 | 0,137228 | |
| Phenylacetoxytrimethylsilane | 2078-18-4 | 0,352872 | |
| Butanedioic acid, bis(trimethylsilyl) ester | 40309-57-7 | 0,431288 | |
| Glyceric acid (3TMS) | 38191-87-6 | 0,09802 | |
| Nonanoic acid trimethylsilyl ester | 82326-11-2 | 0,176436 | |
| Benzaldehyde, p-(trimethylsiloxy)-(7CI,8CI) | 1012-12-0 | 0,058812 | |
| Decanoic acid, trimethylsilyl ester | 55494-15-0 | 0,235248 | |
| 4’-(Trimethylsilyloxy)acetophenone | 18803-29-7 | 0,470496 | |
| malatate | 65143-63-7 | 0,29406 | |
| Trimethylsilylvanillin | 6689-43-6 | 0,176436 | |
| (S)-dihydroactinidiolide | 17092-92-1 | 0,842972 | |
| a-[(Trimethylsilyl)oxy]benzenepropionic acid trimethylsilyl ester | 27750-45-4 | 0,09802 | |
| Benzoic acid,4-[(trimethylsilyl)oxy]-, trimethylsilyl ester | 2078-13-9 | 0,646932 | |
| 4-Methoxy-3-(trimethylsiloxy)benzoic acid methyl ester | 55590-91-5 | 0,548912 | |
| Benzoic acid, 3,4-bis[(trimethylsilyl)oxy]-, methyl ester | 27798-58-9 | 1,137032 | |
| Nonanedioic acid bis(trimethylsilyl) ester | 17906-08-0 | 2,019212 | |
| Protocatechuic acid, di-TMS | 2347-40-2 | 0,999804 | |
| Tetradecanoic acid trimethylsilyl ester | 18603-17-3 | 1,097824 | |
| 3 -Methoxy-4-[(trimethylsilyl)oxy]benzenepropionic acid trimethylsilyl ester | 56051-49-1 | 0,823368 | |
| Benzoic acid,3,5-dimethoxy-4-[(trimethylsilyl)oxy]-, trimethylsilyl ester | 10517-29-0 | 0,9802 | |
| 3-[3-[(Trimethylsilyl)oxy]phenyl]propenoic acid trimethylsilyl ester | 32342-01-1 | 0,999804 | |
| 1,11-Undecanedioic acid, di(trimethylsilyl) ester | 106450-25-3 | 0,842972 | |
| 3-[3,4-Bis(trimethylsilyloxy)phenyl]propenoic acid methyl ester | 22020-29-7 | 2,372084 | |
| 2-Propenoic acid, 3-[3,4-bis[(trimethylsilyl)oxy]phenyl]-, trimethylsilyl ester | 10586-03-5 | 1,86238 | |
| ALMITIC ACID N-BUTYL ESTER | 111-06-8 | 1,431092 | |
| Linoleic acid trimethylsilyl | 56259-07-5 | 15,89884 | |
| Octadecanoic acid, trimethylsilyl ester | 18748-91-9 | 4,901 | |
| Eicosanoic acid, trimethylsilyl ester | 55530-70-6 | 2,078024 | |
| Hexadecanoic acid 2,3-bis[(trimethylsilyl)oxy]propyl ester | 1188-74-5 | 8,586552 | |
| Docosanoic acid trimethylsilyl ester | 74367-36-5 | 2,920996 | |
| Stearic acid 2,3-bis(trimethylsilyloxy)propyl ester | 1188-75-6 | 4,587336 | |
| Podophyllotoxin | 518-28-5 | 17,89845 | |
| Quercetin, penta-TMS | 4067-66-7 | 22,95824 |
Compounds present in the hexanic extarct of Ormenis eiriolepis identified by CG/MS
| RT | identified compounds | cas numbers | % Area |
|---|---|---|---|
| 2-(Trimethylsiloxy)propanoic acid trimethylsilyl ester | 17596-96-2 | 0,14554795 | |
| Hexanoic acid, trimethylsilyl ester | 14246-15-2 | 0,06849315 | |
| Glycolic acid, bis-TMS | 33581-77-0 | 0,08561644 | |
| Octanoic acid, trimethylsilyl ester | 55494-06-9 | 0,08561644 | |
| Nonanoic acid trimethylsilyl ester | 82326-11-2 | 0,11986301 | |
| Decanoic acid, trimethylsilyl ester | 55494-15-0 | 0,65924658 | |
| alpha-curcumene | 644-30-4 | 7,07191781 | |
| (+) -aromadendrene | 489-39-4 | 0,72773973 | |
| (S)-dihydroactinidiolide | 17092-92-1 | 0,10273973 | |
| alpha-Bisabolol | 515-69-5 | 5,49657534 | |
| Nonanedioic acid bis(trimethylsilyl) ester | 17906-08-0 | 0,39383562 | |
| Tetradecanoic acid trimethylsilyl ester | 18603-17-3 | 0,65924658 | |
| Hexadecanoic acid, trimethylsilyl ester | 55520-89-3 | 4,29794521 | |
| Heptadecanoic acid, trimethylsilyl ester | 55517-58-3 | 0,64212329 | |
| 1,2-Hexadecanediol | 6920-24-7 | 0,59075342 | |
| Linoleic acid trimethylsilyl | 56259-07-5 | 9,76883562 | |
| alpha-Linolenic acid, trimethylsilyl ester | 97844-13-8 | 15,3424658 | |
| Octadecanoic acid, trimethylsilyl ester | 18748-91-9 | 2,43150685 | |
| Eicosanoic acid, trimethylsilyl ester | 55530-70-6 | 1,27568493 | |
| 1-Docosanol | 661-19-8 | 6,59246575 | |
| Hexadecanoic acid 2,3-bis[(trimethylsilyl)oxy]propyl ester | 1188-74-5 | 3,3989726 | |
| Docosanoic acid trimethylsilyl ester | 74367-36-5 | 2,40582192 | |
| 1-TETRACOSANOL | 506-51-4 | 7,32020548 | |
| Icosanoic acid 2,3-bis(trimethylsilyloxy)propyl ester | 55517-94-7 | 1,54109589 | |
| Hexacosanoic Acid | 506-46-7 | 2,66267123 | |
| CAMPESTEROL | 474-62-4 | 4,41780822 | |
| Stigmasterol trimethylsilyl ether | 14030-29-6 | 14,0839041 | |
| β-Sitosteryl trimethylsilyl ether | 2625-46-9 | 7,49143836 |
Figure 9(A) Chemical structures of the major bioactive compounds of Ormenis eriolepis Dichloromethane Fraction. (B) Chemical structures of the major bioactive compounds of Ormenis eriolepis Hexanic Extract.